# Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

> **NCT02595866** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 58 (actual)

## Conditions studied

- AIDS-Related Non-Hodgkin Lymphoma
- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Hepatocellular Carcinoma
- HIV Infection
- Kaposi Sarcoma
- Locally Advanced Lung Non-Small Cell Carcinoma
- Locally Advanced Malignant Solid Neoplasm
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Malignant Solid Neoplasm
- Metastatic Melanoma
- Non-Hodgkin Lymphoma
- Recurrent Classic Hodgkin Lymphoma
- Recurrent Malignant Neoplasm
- Refractory Classic Hodgkin Lymphoma
- Refractory Malignant Neoplasm
- Stage III Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Unresectable Melanoma

## Interventions

- **DRUG:** Antiretroviral Therapy
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Pembrolizumab
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT02595866
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-04
- **Primary completion:** 2023-10-04
- **Final completion:** 2024-03-25
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02595866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02595866, "Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02595866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*